Effect of mitotane on pituitary corticotrophs in clinically normal dogs

American Journal of Veterinary Research

Volumn 67, Issue 8, 2006, Pages 1385-1394

  Taoda, Takahiro ^a   Hara, Yasushi ^a   Takekoshi, Susumu ^b   Itoh, Johbu ^b   Teramoto, Akira ^b,c   Osamura, Robert Y ^b   Tagawa, Masahiro ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; MITOTANE; POTASSIUM; SODIUM; TETRACOSACTIDE;

ADRENAL CORTEX; ADRENAL CORTEX DISEASE; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOG; FEMALE; HISTOPATHOLOGY; HORMONE RELEASE; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS DISEASE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POTASSIUM BLOOD LEVEL; RANDOMIZATION; SODIUM BLOOD LEVEL;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CORTICOTROPIN-RELEASING HORMONE; DOGS; FEMALE; HEALTH; MALE; MITOTANE; PITUITARY GLAND;

ANIMALIA; CANIS FAMILIARIS;

EID: 33747778378     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.8.1385     Document Type: Article

References (62)

1. Behrend EN, Kemppainen RJ. Diagnosis of canine hyperadrenocorticism. Vet Clin North Am Small Anim Pract 2001;31:985-1003.
2. Braddock JA. Diagnosis of hyperadrenocorticism in the dog. Aust Vet J 2003;81:25-27.
3. Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med 2003;138:980-991.
4. Thuroczy J, Balogh L, Huszenicza G, et al. Diagnosis of hyperadrenocorticism in dogs as compared to human diagnostic methods: a review. Acta Vet Hung 1998;46:157-173.
5. Hara Y, Ogasawara S, Sako T, et al. Successful treatment of pituitary macroadenoma with transsphenoidal hypophysectomy in a dog. Jpn J Vet Anesth Surg 2003;34:29-36.
6. Hara Y, Tagawa M, Masuda H, et al. Transsphenoidal hypophysectomy for four dogs with pituitary ACTH-producing adenoma. J Vet Med Sci 2003;65:801-804.
7. Peterson ME. Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing's disease). Vet Clin North Am Small Anim Pract 2001;31:1005-1014.
8. Hanson JM, Van't HM, Voorhout G, et al. Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005;19:687-694.
9. Meij BP. Hypophysectomy as a treatment for canine and feline Cushing's disease. Vet Clin North Am Small Anim Pract 2001;31:1015-1041.
10. Kintzer PP, Peterson ME. Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1991;5:182-190.
11. Peterson ME, Kintzer PP. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane. Vet Clin North Am Small Anim Pract 1997;27:255-272.
12. Jensen BL, Caldwell MW, French LG, et al. Toxicity, ultrastructural effects, and metabolic studies with 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane(o,p'-DDD) and its methyl analog in the guinea pig and rat. Toxicol Appl Pharmacol 1987;87:1-9.
13. Lindhe O, Skogseid B, Brandt I. Cytochrome P450-catalyzed binding of 3-methylsulfonyl- DDE and o,p'-DDD in human adrenal zona fasciculata/ reticularis. J Clin Endocrinol Metab 2002;87:1319-1326.
14. Nelson RW, Ihle SL, Feldman EC. Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981-1986). J Am Vet Med Assoc 1989;194:1612-1617.
15. Sarfaty D, Carrillo JM, Peterson ME. Neurologic, endocrinologic, and pathologic findings associated with large pituitary tumors in dogs: eight cases (1976-1984). J Am Vet Med Assoc 1988;193:854-856.
16. Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression [in Portuguese]. Rev Bras Psiquiatr 2004;26:189-201.
17. Young EA, Lopez JF, Murphy-Weinberg V, et al. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 1998;83:3339-3345.
18. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2002;2:836-849.
19. Lamberts SW. Glucocorticoid receptors and Cushing's disease. Mol Cell Endocrinol 2002;197:69-72.
20. Frank LA, DeNovo RC, Kraje AC, et al. Cortisol levels following stimulation of healthy and adrenopathic dogs with two doses of tetracosactrin. J Small Anim Pract 2000;41:308-311.
21. Hansen B, Kemppainen RJ, MacDonald JM. Synthetic ACTH (cosyntropin) stimulation tests in normal dogs: comparison of intravenous and intramuscular administration. J Am Anim Hosp Assoc 1994;30:38-41.
22. Kerl ME, Peterson ME, Wallace MS, et al. Evaluation of a low-dose synthetic adrenocorticotropic hormone stimulation test in clinically normal dogs and dogs with naturally developing hyperadrenocorticism. J Am Vet Med Assoc 1999;214:1497-1501.
23. Ginel PJ, Perez-Rico A, Moreno P, et al. Validation of a commercially available enzyme- linked immunosorbent assay (ELISA) for the determination of cortisol in canine plasma samples. Vet Res Commun 1998;22:179-185.
24. Odagiri E, Demura R, Demura H, et al. The changes in plasma cortisol and urinary free cortisol by an overnight dexamethasone suppression test in patients with Cushing's disease. Endocrinol Jpn 1988;35:795-802.
25. Moore GE, Hoenig M. Duration of pituitary and adrenocortical suppression after long-term administration of anti-inflammatory doses of prednisone in dogs. Am J Vet Res 1992;53:716-720.
26. Ng PC, Lam CW, Lee CH, et al. Reference ranges and factors affecting the human corticotropin-releasing hormone test in preterm, very low birth weight infants. J Clin Endocrinol Metab 2002;87:4621-4628.
27. Reusch CE, Steffen T, Hoerauf A. The efficacy of L-Deprenyl in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1999;13:291-301.
28. Scott-Moncrieff JC, Koshko MA, Brown JA, et al. Validation of a chemiluminescent enzyme immunometric assay for plasma adrenocorticotropic hormone in the dog. Vet Clin Pathol 2003;32:180-187.
29. Bertoy EH, Feldman EC, Nelson RW, et al. Magnetic resonance imaging of the brain in dogs with recently diagnosed but untreated pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1995;206:651-656.
30. Duesberg CA, Feldman EC, Nelson RW, et al. Magnetic resonance imaging for diagnosis of pituitary macrotumors in dogs. J Am Vet Med Assoc 1995;206:657-662.
31. Graham JP, Roberts GD, Newell SM. Dynamic magnetic resonance imaging of the normal canine pituitary gland. Vet Radiol Ultrasound 2000;41:35-40.
32. Kooistra HS, Voorhout G, Mol JA, et al. Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 1997;152:387-394.
33. Watson AD, Rijnberk A, Moolenaar AJ. Systemic availability of op'-DDD in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism. Res Vet Sci 1987;43:160-165.
34. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003;112:1603-1618.
35. Pulichino AM, Vallette-Kasic S, Tsai JP, et al. Tpit determines alternate fates during pituitary cell differentiation. Genes Dev 2003;17:738-747.
36. Capen CC, Martin SL, Koestner A. Neoplasms in the adenohypophysis of dogs: a clinical and pathologic study. Pathol Vet 1967;4:301-325.
37. Peterson ME, Krieger DT, Drucker WD, et al. Immunocytochemical study of the hypophysis in 25 dogs with pituitary-dependent hyperadrenocorticism. Acta Endocrinol (Copenh) 1982;101:15-24.
38. Feldman EC, Nelson RW, Feldman MS, et al. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs. J Am Vet Med Assoc 1992;200:1642-1647.
39. Den Hertog E, Braakman JC, Teske E, et al. Results of non-selective adrenocorticolysis by o,p'-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 1999;144:12-17.
40. Peterson ME. o,p'-DDD (mitotane) treatment of canine pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1983;182:527-528.
41. Peterson ME, Kintzer PP. Medical treatment of pituitary-dependent hyperadrenocorticism in dogs. Semin Vet Med Surg (Small Anim) 1994;9:127-131.
42. Nelson RW, Feldman EC, Shinsako J. Effect of o,p'DDD therapy on endogenous ACTH levels in dogs with hypophysis-dependent hyperadrenocorticism. Am J Vet Res 1985;46:1534-1537.
43. Peterson ME, Orth DN, Halmi NS, et al. Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Addison's disease and Cushing's syndrome: basal levels. Endocrinology 1986;119:720-730.
44. Kasperlik-Zaluska AA, Nielubowicz J, Wislawski J, et al. Nelson's syndrome: incidence and prognosis. Clin Endocrinol (Oxf) 1983;19:693-698.
45. Kaminsky N, Luse S, Hartroft P. Ultrastructure of adrenal cortex of the dog during treatment with DDD. J Natl Cancer Inst 1962;29:127-159.
46. Schteingart DE, Sinsheimer JE, Counsell RE, et al. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Cancer Chemother Pharmacol 1993;31:459-466.
47. Meij BP. Hypophysectomy in dogs: a review. Vet Q 1999;21:134-141.
48. Gould SM, Baines EA, Mannion PA, et al. Use of endogenous ACTH level and adrenal ultrasonography to distinguish the cause of canine hyperadrenocorticism. J Small Anim Pract 2001;42:113-121.
49. Kasperlik-Zaluska A, Niegowska E, Migdalska B, et al. A correlative study between cortisol and ACTH in Cushing's disease following bilateral adrenalectomy and in Nelson's syndrome. Endokrynol Pol 1992;43:314-321.
50. Saeed-uz-Zafar M, Mellinger RC, Wisgerhof M. Cushing's disease: dilemmas of diagnosis and management. Henry Ford Hosp Med J 1991;39:10-17.
51. Moriarty GC, Tobin RB. An immunocytochemical study of TSH beta storage in rat thyroidectomy cells with and without D or L thyroxine treatment. J Histochem Cytochem 1976;24:1140-1149.
52. Ozawa H. Changing ultrastructure of thyrotrophs in the rat anterior pituitary after thyroidectomy as studied by immuno-electron microscopy and enzyme cytochemistry. Cell Tissue Res 1991;263:405-412.
53. Stratmann IE, Ezrin C, Sellers EA, et al. The origin of thyroidectomy cells as revealed by high resolution radioautography. Endocrinology 1972;90:728-734.
54. Dada MO, Campbell GT, Blake CA. Pars distalis cell quantification in normal adult male and female rats. J Endocrinol 1984;101:87-94.
55. Nakane PK, Setalo G, Mazurkiewicz JE. The origin of ACTH cells in rat anterior pituitary. Ann N Y Acad Sci 1977;297:201-204.
56. McNicol AM, Carbajo-Perez E. Aspects of anterior pituitary growth, with special reference to corticotrophs. Pituitary 1999;1:257-268.
57. Ironside JW. Best Practice No 172: pituitary gland pathology. J Clin Pathol 2003;56:561-568.
58. Kemppainen RJ, Zenoble RD. Non-dexamethasone-suppressible, pituitary-dependent hyperadrenocorticism in a dog. J Am Vet Med Assoc 1985;187:276-278.
59. Sarfaty D, Carrillo JM, Patnaik AK. Neurologic, endocrinologic, and pathologic findings associated with large pituitary tumors in dogs: eight cases (1976-1984). J Am Vet Med Assoc 1988;193:854-856.
60. Feldman EC, Nelson RW, Feldman MS. Use of low- and high-dose dexamethasone tests for distinguishing pituitary-dependent from adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc 1996;209:772-775.
61. Kipperman BS, Feldman EC, Dybdal NO, et al. Pituitary tumor size, neurologic signs, and relation to endocrine test results in dogs with pituitary-dependent hyperadrenocorticism: 43 cases (1980-1990). J Am Vet Med Assoc 1992;201:762-767.
62. Nelson RW, Feldman EC, Shinsako J. Effect of o,p'DDD therapy on endogenous ACTH concentrations in dogs with hypophysis-dependent hyperadrenocorticism. Am J Vet Res 1985; 46:1534-1537.